Evidence map›Paper›PMID 20726819›Full record

ReviewTissue engineering. Part B, Reviews2010

Regenerative therapy after cancer: what are the risks?

Vera S Donnenberg, Ludovic Zimmerlin, Joseph Peter Rubin, Albert D Donnenberg

Open access · greenAbstract readReview
In one paragraph

Review in Tissue engineering. Part B, Reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Adipose Tissue-Derived Stem Cells in Regenerative Medicine.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2016
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Vera S DonnenbergUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA. donnenbergvs@upmc.edu
Ludovic Zimmerlin
Joseph Peter Rubin
Albert D Donnenberg
UPMC Hillman Cancer Center · USMcGowan Institute for Regenerative Medicine · USUniversity of Pittsburgh · US

Funding

Injectable Engineered Tissue for Cancer ReconstructionR01CA114246 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RUBIN, J PETER · 2006 to 2019
$3.3M
NCI NIH HHS R01 CA114246NCI NIH HHS R01CA114246NHLBI NIH HHS N01 HB 37165
6 · The paper itself

Abstract

There is often a pressing need for reconstruction after cancer surgery. Regenerative therapy holds the promise of more natural and esthetic functional tissue. In the case of breast reconstruction postmastectomy, volume retention problems associated with autologous fat transfer could be ameliorated by augmentation with cells capable mediating rapid vascularization of the graft. Intentional placement of regenerating tissue at the site of tumor resection raises questions concerning the possibility of promoting cancer recurrence. Here we review coculture and animal models of tumor/mesenchymal stem cell interactions under regenerating conditions. Available evidence from case reports, cell lines, and clinical isolates favors the interpretation that regenerating tissue promotes the growth of active, high-grade tumor. In contrast, dormant cancer cells do not appear to be activated by the complex signals accompanying wound healing and tissue regeneration, suggesting that engineered tissue reconstruction should be deferred until cancer remission has been firmly established.

Indexed as

Regenerative MedicineAnimalsHumansModels, BiologicalNeoplasmsRisk FactorsStem CellsTransplantation, Autologous

Identifiers

PMID20726819
PMCPMC3011999
OpenAlexW2095476582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.